Mark E. Dudley
Impact in
- Oncology top 0.02%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunology top 0.05%
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
Papers in
- Immunology 38
- Immunotherapy and Immune Responses 33
- T-cell and B-cell Immunology 3
- Oncology 34
- CAR-T cell therapy research 25
- Cancer Immunotherapy and Biomarkers 6
- Cutaneous Melanoma Detection and Management 2
- Co-authors
- Steven A. Rosenberg (87 shared papers)Nicholas P. Restifo (20 shared papers)John R. Wunderlich (34 shared papers)James Chih-Hsin Yang (19 shared papers)Richard A. Morgan (12 shared papers)Paul F. Robbins (23 shared papers)Richard Mark Sherry (20 shared papers)James Chih‐Hsin Yang (11 shared papers)
- Journals
- Journal of Immunotherapy (18 papers)The Journal of Immunology (14 papers)Blood (13 papers)Clinical Cancer Research (10 papers)Journal of Clinical Oncology (7 papers)
- Partner nations
- United StatesIsraelCanada
In The Last Decade
Mark E. Dudley
123 papers receiving 38.4k citations
Mark E. Dudley's Hit Papers
Peers
Comparison fields: 5 of 98
- Oncology 15.8k
- Immunology 7.9k
- Genetics 558
- Modeling and Simulation 149
- Hematology 502
Countries citing papers authored by Mark E. Dudley
This map shows the geographic impact of Mark E. Dudley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Dudley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Dudley more than expected).
Fields of papers citing papers by Mark E. Dudley
This network shows the impact of papers produced by Mark E. Dudley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Dudley. The network helps show where Mark E. Dudley may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Dudley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 124 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes Hit paper breakdown → | 2002 | 2329 |
| 2 | Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 Hit paper breakdown → | 2010 | 2177 |
| 3 | Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Hit paper breakdown → | 2006 | 2157 |
| 4 | Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy Hit paper breakdown → | 2011 | 1788 |
| 5 | Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Hit paper breakdown → | 1998 | 1552 |
| 6 | Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Hit paper breakdown → | 2009 | 1513 |
| 7 | Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer Hit paper breakdown → | 2014 | 1459 |
| 8 | Adoptive immunotherapy for cancer: harnessing the T cell response Hit paper breakdown → | 2012 | 1407 |
| 9 | Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Hit paper breakdown → | 2014 | 1385 |
| 10 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy Hit paper breakdown → | 2008 | 1373 |
| 11 | Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1 Hit paper breakdown → | 2011 | 1368 |
| 12 | Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma Hit paper breakdown → | 2005 | 1359 |
| 13 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells Hit paper breakdown → | 2011 | 1250 |
| 14 | Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Hit paper breakdown → | 2009 | 1187 |
| 15 | Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Hit paper breakdown → | 2010 | 1137 |
| 16 | Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens Hit paper breakdown → | 2008 | 1126 |
| 17 | Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy Hit paper breakdown → | 2013 | 972 |
| 18 | PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors Hit paper breakdown → | 2014 | 926 |
| 19 | T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis Hit paper breakdown → | 2010 | 872 |
| 20 | A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response Hit paper breakdown → | 2014 | 682 |
About Mark E. Dudley
Mark E. Dudley is a scholar working on Immunology, Oncology, Plant Science, Genetics and Sensory Systems, having authored 124 papers that have together received 39.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (33 papers), CAR-T cell therapy research (25 papers), Cancer Immunotherapy and Biomarkers (6 papers), Legume Nitrogen Fixing Symbiosis (4 papers), T-cell and B-cell Immunology (3 papers), Virus-based gene therapy research (3 papers), Plant Molecular Biology Research (2 papers) and Cutaneous Melanoma Detection and Management (2 papers). The work is most often cited by research in Oncology (15.8k citations), Immunology (7.9k citations), Genetics (558 citations), Modeling and Simulation (149 citations) and Hematology (502 citations). Mark E. Dudley has collaborated with scholars based in United States, Israel and Canada. Frequent co-authors include Steven A. Rosenberg, Nicholas P. Restifo, John R. Wunderlich, James Chih-Hsin Yang, Richard A. Morgan, Paul F. Robbins, Richard Mark Sherry, James Chih‐Hsin Yang, Donald Edward White and Carolyn M. Laurençot. Their work appears in journals such as Journal of Immunotherapy, The Journal of Immunology, Blood, Clinical Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.